FOXBOROUGH, Mass.--(BUSINESS WIRE)--Aug. 23, 2006--Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: CYKN; “Cyberkinetics”) announced that preliminary results from the pilot trials of Cyberkinetics’ BrainGate Neural Interface System (BrainGate) were presented at the Neural Interfaces Workshop in Bethesda, Maryland, sponsored by the National Institute of Neurological Disorders and Stroke. The report included the first update on a participant with Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease).
